TB-HIV co-infection: a catastrophic comradeship (Q39826708)

15 September 2017

TB-HIV co-infection: a catastrophic comradeship (English)

1 reference

15 September 2017

0 references

2

S Swaminathan

0 references

author name string

G Narendran

series ordinal

1

1 reference

15 September 2017

1 April 2016

1 reference

15 September 2017

1 reference

15 September 2017

22 Suppl 1

1 reference

15 September 2017

46-52

1 reference

Integration of antiretroviral therapy with tuberculosis treatment

15 September 2017

1 reference

An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection

21 January 2018

1 reference

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy

21 January 2018

1 reference

Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy.

21 January 2018

1 reference

Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction

21 January 2018

1 reference

Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa

21 January 2018

1 reference

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

21 January 2018

1 reference

Immune reconstitution disease associated with mycobacterial infections

21 January 2018

1 reference

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study

21 January 2018

1 reference

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

21 January 2018

1 reference

Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, Thailand

21 January 2018

1 reference

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

21 January 2018

1 reference

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts

21 January 2018

1 reference

Treatment outcomes of patients with HIV and tuberculosis.

21 January 2018

1 reference

Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction

21 January 2018

1 reference

Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy

21 January 2018

1 reference

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

21 January 2018

1 reference

Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa

21 January 2018

1 reference

Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease.

21 January 2018

1 reference

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ODI.12389

1 reference

15 September 2017

1 reference

PubMed ID

27109272